Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maternal dTpa immunogenicity and safety study in healthy pregnant women in Japan
jRCT2031260190Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of diphtheria toxoid + tetanus toxoid + acellular pertussis in pertussis, sponsored by GSK. Primary endpoints: Seropositivity for pertussis antibodies 1 month after vaccination and Cord blood seropositivity for pertussis antibodies at birth. Started Jun 2026; status: active, not recruiting.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis
03
Conditions
pertussis
Beyond the preview
Go deeper on jRCT2031260190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260190.